While the live shingles vaccine has already shown signs of protection against dementia, the new combined vaccine offers even more promising results, with far-reaching public health implications
Researchers have discovered a significant link between the combined shingles vaccine and reducing the risk of developing dementia, according to a new study published in the journal "Nature Medicine". While the live shingles vaccine has already shown signs of protection against dementia, the new combined vaccine offers even more promising results, with far-reaching public health implications.
The Varicella-Zoster Virus, the same virus that causes chickenpox and shingles, is considered one of the possible causes of dementia. The relationship between viral infections and neurological diseases, such as dementia, has been studied for many years, when now a new aspect has emerged related to the effect of the vaccine on preventing the development of dementia. The live vaccine for shingles, which was used in the United States and many other countries, was recently replaced by a combined vaccine with advanced technology, designed to provide better and more stable protection. Until now, it was unclear whether the combined vaccine offered the same level of protection against dementia as the live vaccine, so the current study aims to answer this important question.
Results of the study
The researchers took advantage of the rapid transition from the live vaccine to the combined vaccine to examine the effects of the combined vaccine on dementia risk. By analyzing data from over 100,000 patients, the researchers compared the rate of dementia cases among those who received the combined vaccine versus those who received the live vaccine. The study found that people who received the combined vaccine had a lower risk of developing dementia in the six years after vaccination compared to those who received the live vaccine, indicating important potential benefits of the new vaccine in protecting against neurological diseases.
The researchers reported a 17% increase in the age of dementia diagnosis in the recipients of the combined vaccine, which translates to 164 more days of life without a dementia diagnosis among those affected later. These results illustrate the potential of the combined vaccine not only in reducing the risk of shingles, but also as protection against other diseases resulting from viral diseases. The effect was also evident when compared to other vaccines given to older people, such as the flu vaccine and the tetanus-diphtheria-pertussis vaccine, suggesting broader aspects of the protection provided by the combined vaccine.
The effect of gender
The study revealed that the protective effect of the combined vaccine was more significant in women than in men. The researchers found that women who were vaccinated enjoyed a 22% increase in the age of dementia diagnosis, while for men the increase was 13%. These gender differences may be related to different biological or hormonal characteristics between the sexes, and indicate the need for more studies to examine the effects of different types of vaccines on men and women. The findings emphasize the importance of adjusting personal vaccination recommendations based on gender, in order to maximize the health benefits in different populations.
Implications and importance of the study
The results of the study provide a strong basis for conducting further studies, including large-scale clinical trials, to confirm the findings and investigate the biological mechanisms behind the vaccine's protective effect. Understanding how the combined vaccine reduces the risk of dementia can help develop new strategies to prevent neurological diseases. If the results are confirmed, the combined shingles vaccine may be used as an important tool in the fight against dementia in the elderly population, and contribute to improving the quality of life and preventing widespread cognitive decline.
Limitations of the study
As with any study based on observational data, causality cannot be established absolutely. It should be taken into account that there may be other factors that can affect the results, such as differences in the basic health status of the patients. However, the rapid transition from the live to the combined vaccine allowed the researchers to neutralize major biases, such as the health bias of the vaccinated, and compare two groups relatively accurately. The researchers emphasize the need for additional clinical trials to establish the relationship between the combined vaccine and slowing the onset of dementia, and to examine whether the findings can be applied to other population groups.
According to the researchers, the combined vaccine, if finally approved, could be a significant breakthrough in maintaining cognitive health and contribute to improving the quality of life of millions of people around the world.
More of the topic in Hayadan:
One response
The combined vaccine and there is no word on what this vaccine is.